TMCnet News
Good Start Genetics Announces Newest Launch of Next-Generation Embryo Screening ProductGood Start Genetics, Inc., a family genetics information solutions company, announced today the availability of an even more advanced embryo screening offering, with greater affordability for patients, based on its own proprietary sequencing platform and technology exclusively licensed from Johns Hopkins University. This enhanced version of EmbryVu, the company's preimplantation genetic screening (PGS) test, has been developed to enable detection of segmental aneuploidies, in addition to whole chromosome gain or loss. Because EmbryVu helps fertility specialists select embryos for transfer that have a normal chromosome complement, it is expected to significantly increase the chances of a successful pregnancy following IVF. "Given the global market opportunity for PGS and the need for better embryo screening at affordable prices, we intend to continue to invest in this very important product area to help even more IVF customers further improve pregnancy rates with the best technologies at prices they can afford," said Jeffrey Luber, president and chief executive officer of Good Start Genetics."We will continue to pursue other genetic testing areas where our scientific lead, cost advantages, and national footprint can have broad impact." This enhanced version of EmbryVu is available through IVF centers across the country, including IVF centers in the state of New York where the company recently received approval for its newest release.
About Good Start Genetics®, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005649/en/ |